Publication:
Bladderpreservationalternativesin non-metastaticmuscle-invasivebladder tumor:Asystematicreviewand meta-analysis

Simple item page
dc.contributor.authorParrao, Diego
dc.contributor.authorLizana, Nemecio
dc.contributor.authorSaavedra, Catalina
dc.contributor.authorFernandez, Valentina
dc.contributor.authorLindsay, Carolina
dc.contributor.authorLarrañaga, Matıas
dc.contributor.authorFernández Arancibia, Mario
dc.contributor.authorBravo. Juan
dc.date.accessioned2026-08-06T16:31:48Z
dc.date.available2026-08-06T16:31:48Z
dc.date.issued2025
dc.description.abstractObjective: To systematically review the most recent scientific literature regarding modern strategies for organ preservation in the treatment of non-metastatic muscle-invasive bladder cancer. Methods: Literature search was made using PubMed, Google Scholar, EMBASE, Wiley Library, and ClinicalTrials.gov following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. The primary outcome was 5-year overall survival rate, which was addressed by a systematic review and meta-analysis. The risk of bias and quality of evidence were assessed according to the Cochrane Collaboration and the Grading of Recommendations, Assessment, Development and Evaluation system. Results: The evidence is consistent in showing that 5-year survival of trimodality therapy is similar to radical cystectomy in selected patients, ranging between 29% and 73%. Patients undergoing bladder-sparing therapy were found to have better outcomes in terms of quality of life and sociability than those undergoing radical cystectomy. Immunotherapy is establishing itself as a strategy for organ-preservation treatment, showing complete response rates between 42% and 100%. However, most of these results have been obtained from ongoing clinical trials. Furthermore, there are still no studies comparing the efficacy among the different available therapies. Conclusion: Although radical cystectomy remains the gold standard treatment for muscle-invasive bladder cancer, its significant morbidity has prompted the exploration of alternative therapies. In this context, bladder preservation therapies, though supported by limited literature, emerge as a potential alternative that could offer comparable oncological outcomes in selected patients.
dc.description.versionVersión Aceptada
dc.identifier.citationParrao D, Lizana N, Saavedra C, Fernández V, Lindsay CB, Larrañaga M, Fernández MI, Bravo JC. Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor: A systematic review and meta-analysis. Asian J Urol. 2025 Jul;12(3):309-319. doi: 10.1016/j.ajur.2024.08.005
dc.identifier.doihttps://doi.org/10.1016/j.ajur.2024.08.005
dc.identifier.urihttps://hdl.handle.net/11447/10968
dc.language.isoen
dc.subjectladder-sparing
dc.subjectImmunotherapy
dc.subjectMuscle-invasive bladder cancer
dc.subjectTrimodality therapy
dc.titleBladderpreservationalternativesin non-metastaticmuscle-invasivebladder tumor:Asystematicreviewand meta-analysis
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceAsian journal of urology
dspace.entity.typePublication
relation.isAuthorOfPublicationede82ba9-2e79-4469-8218-3f43121e5e01
relation.isAuthorOfPublication.latestForDiscoveryede82ba9-2e79-4469-8218-3f43121e5e01

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bladder preservation alternative sin non-metastatic muscle-invasive.pdf
Size:
1.08 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services